Compare
Trulieve Cannabis Corp. vs USANA Health Sciences Inc vs Tilray Brands, Inc. vs Cresco Labs Inc.
| Latest fiscal year | Trulieve Cannabis Corp. TRLV | USANA Health Sciences Inc USNA | Tilray Brands, Inc. TLRY | Cresco Labs Inc. CRLBF |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-01-03 | 2026-05-31 | 2025-12-31 |
| Revenue | $1.18B | $925.26M | $915.45M | $655.85M |
| Revenue growth (YoY) | -0.4% | +8.3% | +11.5% | -9.5% |
| Gross margin | 60.2% | 78.3% | 28.4% | 49.5% |
| Operating margin | 12.1% | 4.0% | -6.9% | -4.3% |
| Net margin | -10.3% | 1.2% | -13.3% | -20.6% |
| Net income | -$122.25M | $10.76M | -$121.40M | -$135.41M |
| EPS (Diluted) | -$0.58 | $0.58 | -$1.09 | -$0.38 |
| Operating cash flow | $272.82M | $22.35M | -$69.14M | $72.89M |
| Free cash flow | $228.63M | $8.53M | n/a | $37.75M |
| Cash & equivalents | $255.53M | $158.38M | $225.98M | $57.90M |
| Total assets | $2.70B | $742.91M | $2.33B | $1.20B |
| Total liabilities | $1.55B | $156.64M | $733.14M | $944.80M |
| Shareholders' equity | $1.14B | $533.10M | $1.61B | $340.45M |
| Return on year-end equity | -10.7% | 2.0% | -7.5% | -39.8% |
| Shares outstanding | 192.31M | 18.28M | 131.68M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Trulieve Cannabis Corp. | USANA Health Sciences Inc | Tilray Brands, Inc. | Cresco Labs Inc. |
|---|---|---|---|---|
| Latest | $1.18B Ended 2025-12-31 | $925.26M Ended 2026-01-03 | $915.45M Ended 2026-05-31 | $655.85M Ended 2025-12-31 |
| 1 year earlier | $1.19B Ended 2024-12-31 | $854.50M Ended 2024-12-28 | $821.31M Ended 2025-05-31 | $724.34M Ended 2024-12-31 |
| 2 years earlier | $1.13B Ended 2023-12-31 | $921.01M Ended 2023-12-30 | $788.94M Ended 2024-05-31 | $770.88M Ended 2023-12-31 |
| 3 years earlier | $1.22B Ended 2022-12-31 | $998.60M Ended 2022-12-31 | $627.12M Ended 2023-05-31 | n/a |
| 4 years earlier | $931.93M Ended 2021-12-31 | $1.19B Ended 2022-01-01 | $628.37M Ended 2022-05-31 | n/a |